--- title: "Vanda Pharmaceuticals (VNDA) news: lawsuit" url: "https://aibio.space/companies/vanda-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "VNDA lawsuit news: Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), United States." --- VNDA Vanda Pharmaceuticals Inc. NASDAQ · United States # Vanda Pharmaceuticals (VNDA) news VNDA lawsuit news Legal · 2026-10-29 ## [Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits](https://aibio.space/news/court-rules-teva-apotex-vandas-hetlioz-patent-suits/) A Delaware federal court granted summary judgment of non-infringement for Teva and Apotex in September 2026. Vanda is weighing its options, and its 10-Q also reports a DOJ notice and new generic-drug suits. ## Latest Vanda Pharmaceuticals news We have not published a story on Vanda Pharmaceuticals yet. When there is news, it will appear here. ## Vanda Pharmaceuticals at a glance - **Ticker**: VNDA - **Listing**: NASDAQ - **Country**: United States - **Cash, Sep 30, 2026**: $61.9 million ### Related companies - [Harmony Biosciences Holdings](https://aibio.space/companies/harmony-biosciences/) NASDAQ: HRMY - [Retrieve Medical Holdings](https://aibio.space/companies/retrieve-medical/) OTC: RMHI - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) NASDAQ: ACAD - [Lifecore Biomedical](https://aibio.space/companies/lifecore-biomedical/) NASDAQ: LFCR - [Reviva Pharmaceuticals Holdings](https://aibio.space/companies/reviva-pharmaceuticals/) OTC: RVPH - [Lipocine](https://aibio.space/companies/lipocine/) NASDAQ: LPCN - [Vaxxinity](https://aibio.space/companies/vaxxinity/) OTC: VAXX - [ProtoKinetix](https://aibio.space/companies/protokinetix/) OTC: PKTX ### Also on NASDAQ - [Sagimet Biosciences](https://aibio.space/companies/sagimet-biosciences/) SGMT - [CG Oncology](https://aibio.space/companies/cg-oncology/) CGON - [IRIDEX CORP](https://aibio.space/companies/iridex/) IRIX - [Vivos Therapeutics](https://aibio.space/companies/vivos-therapeutics/) VVOS - [Cronos Group](https://aibio.space/companies/cronos/) CRON - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) ACTU ## What Vanda Pharmaceuticals does Vanda Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing innovative therapies for high unmet medical needs, applying its pharmacogenetics and pharmacogenomics expertise. Its commercial portfolio comprises four products. FANAPT (iloperidone) is approved for schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder. HETLIOZ (tasimelteon) is the first FDA-approved treatment for Non-24-Hour Sleep-Wake Disorder (Non-24) and for nighttime sleep disturbances in Smith-Magenis syndrome. PONVORY (ponesimod) treats relapsing forms of multiple sclerosis, and NEREUS (tradipitant) is marketed for prevention of vomiting induced by motion. In development are a long-acting injectable Fanapt formulation, Bysanti (milsaperidone), the active metabolite of Fanapt, and imsidolimab, an IL-36R antagonist for generalized pustular psoriasis. The company is headquartered in Washington, D.C. | Product or program | What it is | Stage | |---|---|---| | FANAPT (iloperidone) | Treatment for schizophrenia and bipolar I manic or mixed episodes | approved in the US | | HETLIOZ (tasimelteon) | Melatonin agonist for Non-24 and sleep disturbances in Smith-Magenis syndrome | approved in the US | | PONVORY (ponesimod) | Treatment for relapsing forms of multiple sclerosis | commercial product in the US and Canada | | NEREUS (tradipitant) | Prevention of vomiting induced by motion | commercial product | | Bysanti (milsaperidone) | Active metabolite of Fanapt for bipolar I disorder, schizophrenia and major depressive disorder | in development | | imsidolimab | IL-36R antagonist for generalized pustular psoriasis | in development | Summarised from the company's [10-K filed Feb 12, 2026](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm). ## Vanda Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$216.1 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | [$198.8 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | | Research and development | [$109.3 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | [$74.4 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | | Net income (loss) | [-$220.5 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | [-$18.9 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | | Cash from operations | [-$109.4 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | [-$15.8 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | | Cash and equivalents | [$84.9 million](https://www.sec.gov/Archives/edgar/data/1347178/000134717826000002/) | [$102.3 million](https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/) | Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $61.9 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Vanda Pharmaceuticals Is Vanda Pharmaceuticals involved in a lawsuit? Our latest story on this, dated Oct 29, 2026: "Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/court-rules-teva-apotex-vandas-hetlioz-patent-suits/). What is the ticker symbol of Vanda Pharmaceuticals? Vanda Pharmaceuticals Inc. trades under the ticker VNDA on NASDAQ. Where is Vanda Pharmaceuticals listed? Vanda Pharmaceuticals Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:VM4; LS:A0JJT3; LSE:0LKB; LSX:A0JJT3. What is the SEC CIK of Vanda Pharmaceuticals? The SEC Central Index Key (CIK) for Vanda Pharmaceuticals Inc. is 1347178. Its filings are on SEC EDGAR. How many shares does Vanda Pharmaceuticals have outstanding? 60,462,687 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Vanda Pharmaceuticals listed under? Our directory records Vanda Pharmaceuticals Inc. under United States. What does Vanda Pharmaceuticals do? Our directory classifies Vanda Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Vanda Pharmaceuticals? The ISIN recorded for Vanda Pharmaceuticals Inc. is US9216591084. Does aibio.space cover Vanda Pharmaceuticals? aibio.space lists Vanda Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Vanda Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What does Vanda Pharmaceuticals develop? Vanda Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing innovative therapies for high unmet medical needs, applying its pharmacogenetics and pharmacogenomics expertise. Its commercial portfolio comprises four products. What is FANAPT (iloperidone) from Vanda Pharmaceuticals? FANAPT (iloperidone): Treatment for schizophrenia and bipolar I manic or mixed episodes Stage: approved in the US. What is HETLIOZ (tasimelteon) from Vanda Pharmaceuticals? HETLIOZ (tasimelteon): Melatonin agonist for Non-24 and sleep disturbances in Smith-Magenis syndrome Stage: approved in the US. What was Vanda Pharmaceuticals's revenue last year? $216.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Vanda Pharmaceuticals profitable? Vanda Pharmaceuticals Inc. reported a net loss of $220.5 million for the fiscal year ended Dec 31, 2025, and used $109.4 million of cash in operations, per its annual report to the SEC. ## Investor discussion: Vanda Pharmaceuticals Members talk about Vanda Pharmaceuticals (VNDA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Press releases Headlines of Vanda Pharmaceuticals's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-28 PR Newswire [Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-reports-third-quarter-2026-financial-results-302922677.html) 2. 2026-10-27 PR Newswire [Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting](https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-positive-results-from-study-3601-of-nereus-tradipitant-for-prevention-of-glp-1induced-vomiting-302920054.html) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:VNDA on TradingView](https://www.tradingview.com/symbols/NASDAQ-VNDA/). ## SEC filings and registration - **SEC name**: Vanda Pharmaceuticals Inc. - **CIK**: 1347178 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: VNDA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: 2200 PENNSYLVANIA AVE NW, WASHINGTON, DC, 20037 - **Phone**: 202-734-3400 - **Shares outstanding**: 60,462,687 as of 2026-07-30 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053855/vnda-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026041298/vnda-20260604.htm) filed 2026-06-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1347178/000162828026031667/vnda-20260331.htm) filed 2026-05-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda-20260506.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1347178/000162828026026893/vnda-20260423.htm) filed 2026-04-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026026642/vnda-20260422.htm) filed 2026-04-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026023222/vnda-20260329.htm) filed 2026-04-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001347178), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Vanda Pharmaceuticals Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker VNDA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Vanda Pharmaceuticals Inc. - **Ticker**: VNDA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US9216591084 - **Other listed symbols**: GETTEX:VM4; LS:A0JJT3; LSE:0LKB; LSX:A0JJT3 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-VNDA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/vanda-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Vanda Pharmaceuticals (VNDA) news: lawsuit", 2026-10-31, https://aibio.space/companies/vanda-pharmaceuticals/